{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:48:20Z","timestamp":1791672500432,"version":"4.3.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    \u03b2-thalassaemia is a genetic blood disorder characterized by ineffective erythropoiesis and chronic anaemia, often requiring lifelong red blood cell (RBC) transfusions. Luspatercept, an erythroid maturation agent, has emerged as a potential therapy to reduce transfusion burden in affected adults. To assess the clinical efficacy and safety of luspatercept in managing adult patients with \u03b2-thalassemia. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating luspatercept in adult patients with \u03b2-thalassemia. A comprehensive search of PubMed, Scopus, Embase, Cochrane Library, and ClinicalTrials.gov was performed for studies published up to May 2025. Only English-language RCTs were included. Data were extracted on transfusion burden, hemoglobin response, and adverse events. Risk of bias was assessed using the Cochrane ROB 2 tool. Pooled estimates were calculated using a random-effects model with the Freeman\u2013Tukey double arcsine transformation. Heterogeneity was assessed using the I\u00b2 statistic. Out of 587 identified records, three RCTs and one single-arm trial (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009608 patients) met the inclusion criteria. Of these, 447 patients received luspatercept and 161 received placebo. Luspatercept was associated with a\u2009\u2265\u200933% reduction in RBC transfusion burden in 58% (95% CI: 0.33\u20130.79) and a\u2009\u2265\u200950% reduction in 40% (95% CI: 0.25\u20130.58) of patients. Transfusion independence was achieved in 36% (95% CI: 0.13\u20130.69). Common adverse events included headache (32%), bone pain (33%), arthralgia (22%), and back pain (20%). Grade\u2009\u2265\u20093 adverse events occurred in 21% (95% CI: 0.09\u20130.41). Overall, luspatercept effectively reduced transfusion needs with an acceptable safety profile. Luspatercept significantly reduces transfusion burden in patients with \u03b2-thalassemia and demonstrates a manageable safety profile. These findings support luspatercept as an effective and well-tolerated therapeutic option that meaningfully reduces transfusion burden, potentially decreasing iron overload and improving quality of life for patients with \u03b2-thalassemia.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07151-5","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T20:13:14Z","timestamp":1782418394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes with luspatercept in patients with \u03b2-thalassemia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3568-0144","authenticated-orcid":false,"given":"Nihal","family":"Babiker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2087-3297","authenticated-orcid":false,"given":"Eslam","family":"Abady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2878-7311","authenticated-orcid":false,"given":"Hafsa","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2846-5630","authenticated-orcid":false,"given":"Wania Ur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris","family":"Babker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0959-9046","authenticated-orcid":false,"given":"Menna","family":"Sarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8166-720X","authenticated-orcid":false,"given":"Hind","family":"El Azzazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5190-280X","authenticated-orcid":false,"given":"Mohamedelborae Abdalgafar Elimam","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0559-9577","authenticated-orcid":false,"given":"Hafiz Muhammad Hannan","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4872-5603","authenticated-orcid":false,"given":"Yahya","family":"Samadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"7151_CR1","doi-asserted-by":"publisher","first-page":"102619","DOI":"10.1016\/j.eclinm.2024.102619","volume":"72","author":"Y Tuo","year":"2024","unstructured":"Tuo Y, Li Y, Li Y et al (2024) Global, regional, and national burden of thalassemia, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. EClinicalMedicine 72:102619","journal-title":"EClinicalMedicine"},{"key":"7151_CR2","doi-asserted-by":"crossref","unstructured":"Modell B, Darlison M (2008) Global epidemiology of haemoglobin disorders. Bull World Health Organ 86(6)480\u20137","DOI":"10.2471\/BLT.06.036673"},{"issue":"1","key":"7151_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/ijns5010016","volume":"5","author":"M Angastiniotis","year":"2019","unstructured":"Angastiniotis M, Lobitz S, Thalassemias (2019) An Overview. Int J Neonatal Screen 5(1):16","journal-title":"Int J Neonatal Screen"},{"issue":"1","key":"7151_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-5-11","volume":"5","author":"R Galanello","year":"2010","unstructured":"Galanello R, Origa R (2010) Beta-thalassemia. Orphanet J Rare Dis 5(1):1\u201315","journal-title":"Orphanet J Rare Dis"},{"key":"7151_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1196\/annals.1345.006","volume":"1054","author":"C Borgna-Pignatti","year":"2005","unstructured":"Borgna-Pignatti C, Cappellini MD, De Stefano P et al (2005) Survival and complications in thalassemia. Ann N Y Acad Sci 1054:40\u201347","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"7151_CR6","first-page":"85","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A, Luspatercept (2020) First Approval Drugs 80(1):85\u201390","journal-title":"First Approval Drugs"},{"issue":"10","key":"7151_CR7","doi-asserted-by":"publisher","first-page":"e733","DOI":"10.1016\/S2352-3026(22)00208-3","volume":"9","author":"AT Taher","year":"2022","unstructured":"Taher AT, Cappellini MD, Kattamis A et al (2022) Luspatercept for the treatment of anaemia in non-transfusion-dependent \u03b2-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial. Lancet Haematol 9(10):e733\u2013e744","journal-title":"Lancet Haematol"},{"issue":"1","key":"7151_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1182\/bloodadvances.2020002725","volume":"5","author":"MD Cappellini","year":"2021","unstructured":"Cappellini MD, Taher AT (2021) The use of luspatercept for thalassemia in adults. Blood Adv 5(1):326\u2013333","journal-title":"Blood Adv"},{"issue":"13","key":"7151_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","volume":"382","author":"MD Cappellini","year":"2020","unstructured":"Cappellini MD, Viprakasit V, Taher AT et al (2020) A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent \u03b2-Thalassemia. N Engl J Med 382(13):1219\u20131231","journal-title":"N Engl J Med"},{"issue":"5","key":"7151_CR10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/bloodadvances.2020002177","volume":"5","author":"AS Kubasch","year":"2021","unstructured":"Kubasch AS, Fenaux P, Platzbecker U (2021) Development of luspatercept to treat ineffective erythropoiesis. Blood Adv 5(5):1565\u20131575","journal-title":"Blood Adv"},{"issue":"12","key":"7151_CR11","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2217\/fon-2020-1093","volume":"17","author":"O Chan","year":"2021","unstructured":"Chan O, Komrokji RS (2021) Luspatercept in the treatment of lower-risk myelodysplastic syndromes. Future Oncol 17(12):1473\u20131481","journal-title":"Future Oncol"},{"key":"7151_CR12","doi-asserted-by":"crossref","unstructured":"Garbowski MW, Ugidos M, Risue\u00f1o A et al (2023) Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia. Am J Hematol 98(12)182\u2013192","DOI":"10.1002\/ajh.27102"},{"issue":"Supplement 1","key":"7151_CR13","doi-asserted-by":"publisher","first-page":"7417","DOI":"10.1182\/blood-2023-178262","volume":"142","author":"TW Htut","year":"2023","unstructured":"Htut TW, Phyu EM, Zaw MH, Myat YM, Thein KZ (2023) Efficacy and Tolerability of Luspatercept in Patients with Lower Risk Myelodysplastic Syndrome and Anemia: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials. Blood 142(Supplement 1):7417","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07151-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07151-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07151-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:50:32Z","timestamp":1791669032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07151-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":13,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7151"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07151-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"411"}}